Major PBM Looks to Stem Gilead Sciences' (GILD) Hepatitis C Profits
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Merck (MRK) Over-Hyped in Hep C, Says Wells Fargo (GILD) (ABBV)
April 10, 2014 9:23 AM EDTWells Fargo analyst Brian Abrahams said Merck (NYSE: MRK) may be over-hyped as a hepC competitor to Gilead Sciences (NASDAQ: GILD).
"We are attending the EASL conference in London UK, where Merck has just pressreleased additional data from... More
Maxim Remains Positive on Gilead (GILD); Sovaldi is Compelling HCV Treatment from Cost-Benefit Perspective
April 9, 2014 8:50 AM EDTGilead Sciences (Nasdq: GILD) is up early Wednesday following positive commentary out of Maxim Group. The firm has Gilead at Buy with a price target of $101.
Analyst Jason Kolbert, commented, Gilead was pilloried again yesterday for developing a drug (Sovaldi) with the highest efficacy and fewest side effects, but at a high (but not the highest) price for a new... More
Gilead Sciences, Inc. (GILD) Receives FDA Priority Review Date for Ledipasvir + Sofosbuvir NDA as HCV Treatment
April 7, 2014 8:44 AM EDTGilead Sciences, Inc. (Nasdaq: GILD) announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the companys New Drug Application (NDA) for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg for the treatment of chronic hepatitis C genotype 1 infection in adults. Gilead filed the NDA for LDV/SOF on February 10, 2014, and the... More
Blood-Bath in Nasdaq Stocks
April 4, 2014 12:37 PM EDTStocks are under heavy mid-day pressure Friday, led by the blood-letting in high-growth, high-multiple momentum names that litter the Nasdaq. The Nasdaq is down 88 points, or 2%, while the Dow and S&P 400 are lower but down just 0.3% and 0.5%, respectively.
The selling that started in the biotech sector a... More
Gilead Sciences, Inc. (GILD) Sovaldi TRx +4%, NRx +4% - ISI
April 4, 2014 7:23 AM EDTAccording to a tweet from ISI's Mark Schoenebaum, Gilead Sciences, Inc. (NASDAQ: GILD) Sovaldi TRx +4%, NRx +4%.
Schoenebaum included the following chart showing the Sovaldi launch trajectories versus Incivek.
... More